KR102344479B1 - 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 - Google Patents

피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 Download PDF

Info

Publication number
KR102344479B1
KR102344479B1 KR1020140181951A KR20140181951A KR102344479B1 KR 102344479 B1 KR102344479 B1 KR 102344479B1 KR 1020140181951 A KR1020140181951 A KR 1020140181951A KR 20140181951 A KR20140181951 A KR 20140181951A KR 102344479 B1 KR102344479 B1 KR 102344479B1
Authority
KR
South Korea
Prior art keywords
compound
branched
straight
benzyloxy
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020140181951A
Other languages
English (en)
Korean (ko)
Other versions
KR20150075030A (ko
Inventor
유상구
정진욱
조인근
임정호
강구석
김진영
Original Assignee
주식회사 글라세움
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 글라세움 filed Critical 주식회사 글라세움
Priority to US15/037,230 priority Critical patent/US9783551B2/en
Priority to PL14873860T priority patent/PL3098224T3/pl
Priority to SG11201604371PA priority patent/SG11201604371PA/en
Priority to AU2014370697A priority patent/AU2014370697B2/en
Priority to JP2016540481A priority patent/JP6620096B2/ja
Priority to DK14873860.2T priority patent/DK3098224T3/da
Priority to BR112016011281-4A priority patent/BR112016011281B1/pt
Priority to PCT/KR2014/012688 priority patent/WO2015099392A1/ko
Priority to MX2016008429A priority patent/MX374944B/es
Priority to PT14873860T priority patent/PT3098224T/pt
Priority to HRP20190573TT priority patent/HRP20190573T1/hr
Priority to HUE14873860 priority patent/HUE043902T2/hu
Priority to CN201480070935.5A priority patent/CN105849111B/zh
Priority to CA2929001A priority patent/CA2929001C/en
Priority to EP14873860.2A priority patent/EP3098224B1/en
Priority to ES14873860T priority patent/ES2718878T3/es
Priority to NZ720328A priority patent/NZ720328A/en
Priority to TW103145316A priority patent/TWI585093B/zh
Publication of KR20150075030A publication Critical patent/KR20150075030A/ko
Priority to IL245908A priority patent/IL245908B/en
Priority to JP2018056783A priority patent/JP2018135343A/ja
Priority to CY20191100423T priority patent/CY1121554T1/el
Application granted granted Critical
Publication of KR102344479B1 publication Critical patent/KR102344479B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020140181951A 2013-12-24 2014-12-17 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 Active KR102344479B1 (ko)

Priority Applications (21)

Application Number Priority Date Filing Date Title
CN201480070935.5A CN105849111B (zh) 2013-12-24 2014-12-23 吡喃并秋葵纤维异甲酚衍生物以及代谢综合征或炎症疾病治疗用药学组成物
SG11201604371PA SG11201604371PA (en) 2013-12-24 2014-12-23 Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
AU2014370697A AU2014370697B2 (en) 2013-12-24 2014-12-23 Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
JP2016540481A JP6620096B2 (ja) 2013-12-24 2014-12-23 ピラノクロメニルフェノール誘導体、及び代謝症候群または炎症疾患治療用医薬組成物
DK14873860.2T DK3098224T3 (da) 2013-12-24 2014-12-23 Pyranochromenyl-phenolderivat og farmaceutisk sammensætning til behandling af metabolisk syndrom eller inflammationssygdom
BR112016011281-4A BR112016011281B1 (pt) 2013-12-24 2014-12-23 Composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste e composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste
PCT/KR2014/012688 WO2015099392A1 (ko) 2013-12-24 2014-12-23 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물
MX2016008429A MX374944B (es) 2013-12-24 2014-12-23 Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.
PL14873860T PL3098224T3 (pl) 2013-12-24 2014-12-23 Pochodna piranochromenylofenolu i kompozycja farmaceutyczna do leczenia zespołu metabolicznego lub choroby zapalnej
HRP20190573TT HRP20190573T1 (hr) 2013-12-24 2014-12-23 Piranokromenil fenol derivat, i farmaceutska kompozicija za liječenje metaboličkog sindroma ili inflamatorne bolesti
US15/037,230 US9783551B2 (en) 2013-12-24 2014-12-23 Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
CA2929001A CA2929001C (en) 2013-12-24 2014-12-23 Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
HUE14873860 HUE043902T2 (hu) 2013-12-24 2014-12-23 Piranokromenil-fenol származék, és gyógyszerészeti kompozíció metabolikus szindróma vagy gyulladásos betegség kezelésére
PT14873860T PT3098224T (pt) 2013-12-24 2014-12-23 Derivado de piranocromanilfenol, e composição farmacêutica para tratar a síndrome metabólica ou doença inflamatória
ES14873860T ES2718878T3 (es) 2013-12-24 2014-12-23 Derivado de piranocromenilfenol y composición farmacéutica para el tratamiento del síndrome metabólico o la enfermedad inflamatoria
NZ720328A NZ720328A (en) 2013-12-24 2014-12-23 Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
EP14873860.2A EP3098224B1 (en) 2013-12-24 2014-12-23 Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
TW103145316A TWI585093B (zh) 2013-12-24 2014-12-24 供治療代謝症候群或發炎性疾病的吡喃苯并吡喃基苯酚衍生物及醫藥組成物
IL245908A IL245908B (en) 2013-12-24 2016-05-29 Consequences of pyranochromanil phenol and a pharmaceutical preparation for the treatment of metabolic syndrome or inflammatory disease
JP2018056783A JP2018135343A (ja) 2013-12-24 2018-03-23 ピラノクロメニルフェノール誘導体、及び代謝症候群または炎症疾患治療用医薬組成物
CY20191100423T CY1121554T1 (el) 2013-12-24 2019-04-16 Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130162909 2013-12-24
KR1020130162909 2013-12-24

Publications (2)

Publication Number Publication Date
KR20150075030A KR20150075030A (ko) 2015-07-02
KR102344479B1 true KR102344479B1 (ko) 2021-12-29

Family

ID=53788040

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020140181951A Active KR102344479B1 (ko) 2013-12-24 2014-12-17 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물

Country Status (21)

Country Link
US (1) US9783551B2 (cg-RX-API-DMAC10.html)
EP (1) EP3098224B1 (cg-RX-API-DMAC10.html)
JP (2) JP6620096B2 (cg-RX-API-DMAC10.html)
KR (1) KR102344479B1 (cg-RX-API-DMAC10.html)
CN (1) CN105849111B (cg-RX-API-DMAC10.html)
AU (1) AU2014370697B2 (cg-RX-API-DMAC10.html)
BR (1) BR112016011281B1 (cg-RX-API-DMAC10.html)
CA (1) CA2929001C (cg-RX-API-DMAC10.html)
CY (1) CY1121554T1 (cg-RX-API-DMAC10.html)
DK (1) DK3098224T3 (cg-RX-API-DMAC10.html)
ES (1) ES2718878T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20190573T1 (cg-RX-API-DMAC10.html)
HU (1) HUE043902T2 (cg-RX-API-DMAC10.html)
IL (1) IL245908B (cg-RX-API-DMAC10.html)
MX (1) MX374944B (cg-RX-API-DMAC10.html)
NZ (1) NZ720328A (cg-RX-API-DMAC10.html)
PL (1) PL3098224T3 (cg-RX-API-DMAC10.html)
PT (1) PT3098224T (cg-RX-API-DMAC10.html)
SG (1) SG11201604371PA (cg-RX-API-DMAC10.html)
TW (1) TWI585093B (cg-RX-API-DMAC10.html)
WO (1) WO2015099392A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250081177A (ko) 2023-11-29 2025-06-05 한국화학연구원 Hsg4112 r형을 유효성분으로 포함하는 반려동물의 비만 예방, 개선 또는 치료용 조성물

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102344479B1 (ko) * 2013-12-24 2021-12-29 주식회사 글라세움 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물
TWI731998B (zh) 2016-06-29 2021-07-01 南韓商格雷森伍股份有限公司 光學活性吡喃並苯並吡喃基苯酚衍生物及包含其的醫藥組成物
TWI641610B (zh) * 2016-10-04 2018-11-21 南韓商格雷森伍股份有限公司 用於合成3-苯基-2,3,4,8,9,10-六氫吡喃並[2,3-f]色烯衍生物及其光學異構物的方法
TWI804600B (zh) * 2018-04-03 2023-06-11 南韓商格雷森伍股份有限公司 3-苯基-2,8-二氫吡喃[2,3-ƒ]苯并哌喃衍生物的合成方法
WO2019194583A1 (ko) * 2018-04-03 2019-10-10 주식회사 글라세움 3-페닐-2,8-디히드로피라노[2,3-f]크로멘 유도체 및 이를 포함하는 약학적 조성물
KR20200105198A (ko) * 2019-02-28 2020-09-07 주식회사 글라세움 신경계 질환의 예방 또는 치료용 약학적 조성물
KR102692932B1 (ko) 2019-07-30 2024-08-07 주식회사 글라세움 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법
US20250367163A1 (en) 2021-06-08 2025-12-04 Glaceum, Inc. Pharmaceutical composition for preventing or treating degenerative eye diseases
CN113616548B (zh) * 2021-09-02 2023-04-28 河南科技大学 一种水溶性光甘草定包合物及其制备方法
CN119343351A (zh) 2022-04-12 2025-01-21 格拉斯如睦株式会社 用于3-苯基-2,3,4,8,9,10-六氢吡喃并[2,3-f]色烯衍生物的合成方法
CN114903879B (zh) * 2022-06-23 2023-10-31 东北大学 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途
KR20240113389A (ko) 2023-01-12 2024-07-22 주식회사 글라세움 퇴행성 골관절염의 예방 또는 치료용 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050035142A (ko) * 2001-10-11 2005-04-15 카네카 코포레이션 페록시좀 증식제 응답성 수용체 리간드제 및 그 제조 방법
KR100565423B1 (ko) * 2003-10-20 2006-03-30 빅 바이오 주식회사 이소플라반 유도체 또는 이소플라벤 유도체의 제조방법
JP2006008604A (ja) * 2004-06-25 2006-01-12 Kuraray Co Ltd イソフラバン誘導体の製造方法
WO2007058480A1 (en) 2005-11-16 2007-05-24 Md Bioalpha Co., Ltd. Composition having effect on treatment and prevention of diseases syndrome treatment with glabridin
KR102344479B1 (ko) * 2013-12-24 2021-12-29 주식회사 글라세움 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250081177A (ko) 2023-11-29 2025-06-05 한국화학연구원 Hsg4112 r형을 유효성분으로 포함하는 반려동물의 비만 예방, 개선 또는 치료용 조성물

Also Published As

Publication number Publication date
CN105849111A (zh) 2016-08-10
PL3098224T3 (pl) 2019-07-31
JP6620096B2 (ja) 2019-12-11
NZ720328A (en) 2018-02-23
ES2718878T3 (es) 2019-07-05
PT3098224T (pt) 2019-04-26
MX2016008429A (es) 2017-02-23
DK3098224T3 (da) 2019-05-13
CN105849111B (zh) 2018-05-04
HUE043902T2 (hu) 2019-10-28
JP2018135343A (ja) 2018-08-30
BR112016011281B1 (pt) 2021-11-16
AU2014370697B2 (en) 2017-01-19
US9783551B2 (en) 2017-10-10
EP3098224A4 (en) 2017-07-05
US20160272650A1 (en) 2016-09-22
SG11201604371PA (en) 2016-07-28
IL245908B (en) 2020-08-31
EP3098224A1 (en) 2016-11-30
KR20150075030A (ko) 2015-07-02
BR112016011281A2 (cg-RX-API-DMAC10.html) 2017-08-08
MX374944B (es) 2025-03-06
JP2017501163A (ja) 2017-01-12
EP3098224B1 (en) 2019-01-30
CA2929001C (en) 2018-02-20
TW201607949A (zh) 2016-03-01
HRP20190573T1 (hr) 2019-05-17
IL245908A0 (en) 2016-08-02
CY1121554T1 (el) 2020-05-29
AU2014370697A1 (en) 2016-06-16
WO2015099392A1 (ko) 2015-07-02
CA2929001A1 (en) 2015-07-02
TWI585093B (zh) 2017-06-01

Similar Documents

Publication Publication Date Title
JP6620096B2 (ja) ピラノクロメニルフェノール誘導体、及び代謝症候群または炎症疾患治療用医薬組成物
JP7036871B2 (ja) 光学活性ピラノクロメニルフェノール誘導体およびそれを含む薬学的組成物
KR20080027191A (ko) 신규한 벤즈옥사졸 유도체, 이의 제조방법 및 이를포함하는 약학 조성물
JP6977053B2 (ja) ギ酸またはその薬学的に許容可能な塩を有効成分として含む肥満または肥満によって惹起された代謝症候群の予防または治療用組成物
US12545643B2 (en) 3,5-diaminobenzoic acid compound, and Pin1 inhibitor and therapeutic agent for inflammatory diseases using same
HK1227863A1 (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
HK1227863B (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
TW200529807A (en) Remedy
HK40004723B (en) Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same
NZ749461B (en) Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same
HK40004723A (en) Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same
CN120774876A (zh) 金合欢素与4,4’-联吡啶的共晶物及其用途

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5